ClinicalTrials.gg
CompletedNCT06462118Updated Jan 30, 2025

A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

A Phase 1 interventional study of Astegolimab in Healthy Volunteers, sponsored by Genentech, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of ≥50 kg to ≤110 kg with (BMI) range 18.0 to 30.0 kg/m2 (inclusive) at screening

Exclusion criteria

Exclusion Criteria:

  • History of significant or severe allergic reaction, including anaphylaxis, to any drug compound, food, or other substance
  • Any immunization or vaccination 14 days prior to the Check-in (Day -1) or plans to obtain any immunization or vaccination within 30 days after the Check-in
  • Any surgical procedure (except for minor surgeries) within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • Donation of blood from 30 days prior to screening through study completion or end of trial, inclusive, or of plasma from 2 weeks prior to screening through study completion or end of trial, inclusive
  • History of immunodeficiency, including but not limited to, (HIV) infection
  • History of active or untreated latent tuberculosis
  • History of within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
  • Unstable cardiac disease, myocardial infarction, or Class 3 or 4 heart failure within 12 months prior to screening
  • History or presence of abnormalities at screening or check-in (Day -1)
  • Positive for or (HCV)
  • Tattoo(s) or scarring at or near the site of injection (abdomen, front and middle thigh, or upper arm) or any other condition which may interfere with the injection site examination (as determined by the Investigator)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive one subcutaneous (SC) dose in the abdomen.

    Drug: Astegolimab

  • Experimental
    Treatment B

    Participants will receive one subcutaneous (SC) dose in the thigh.

    Drug: Astegolimab

  • Experimental
    Treatment C

    Participants will receive one subcutaneous (SC) dose in the upper arm.

    Drug: Astegolimab

Interventions

  • Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.

06

What researchers measure

Primary outcomes

  1. Area under the curve from Hour 0 to the time of last measurable concentration (AUC0-t) of astegolimab

    Time frame: Approximately 85 days

  2. AUC extrapolated to infinity (AUC0-infinity) of astegolimab

    Time frame: Approximately 85 days

  3. Maximum serum concentration (Cmax) of astegolimab

    Time frame: Approximately 85 days

Secondary outcomes

  1. Relative bioavailability (F%) for thigh injection of astegolimab

    Time frame: Approximately 85 days

  2. F% for upper arm injection of astegolimab

    Time frame: Approximately 85 days

  3. Half-life (T1/2) of astegolimab

    Time frame: Approximately 85 days

  4. Apparent systemic clearance (CL/F) of astegolimab

    Time frame: Approximately 85 days

  5. Apparent volume of distribution during the terminal elimination phase (Vz/F) of astegolimab

    Time frame: Approximately 85 days

  6. Time to maximum serum concentration (Tmax) of astegolimab

    Time frame: Approximately 85 days

  7. Incidence of anti-drug antibodies (ADAs)

    Time frame: Approximately 85 days

07

Study locations

3 sites
  • Covance Research Unit - Daytona
    Daytona Beach, Florida 32117, United States
  • Covance Research Unit - Dallas
    Dallas, Texas 75247, United States
  • Covance Clinical Research Unit, Inc
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Oct 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Jun 17, 2024
Primary completionActual
Oct 22, 2024
CompletionActual
Oct 22, 2024
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06462118
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jun 17, 2024
Primary completion
Oct 22, 2024
Completion
Oct 22, 2024
Last update
Jan 30, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion